|
|
Zhaosheng Lin
Head of Biomarkers
Pfizer
 Nadine Cohen Head of Pharmacogenomics
Johnson & Johnson
 Mitchell B. Friedman Director of Toxicology
Takeda Global R&D
 Malcolm Mitchell Medical Director, Clinical Pharmacology
Eli Lilly
 Dr Russell Weiner Group Director
Bristol-Myers Squibb
|
Conference:
Pre-conference workshop
19 Oct 9am - 5pm
Day 1
20 Oct 8.30am - 5:30pm
Day 2
21 Oct 8.30am - 5:30pm
Post-conference workshop
22 Oct 9am - 5pm
Venue: Boston, MA, United States
› Email a friend
› Add this to my calendar
|
|
|
 Zhaosheng Lin,
Head of Biomarkers Pfizer Inc 1996. Ph.D. in Biochemistry, University of Manitoba, Canada.
1996 – 1999. Postdoctoral fellow, University of Toronto HSC in Mol Cell Biology and Cancer Biology, 1996-1999.
2000 – 2005. Senior Scientist/Group Leader in the biotech industries, focusing mostly on the discovery, development and validation of biomarkers and cancer research.
2006 – 2009. Lab Manager in Biomarker Mass Spec Lab. Wyeth Pharmaceuticals.
2009/5 -2010/3. Head, Biomarker Laboratories, and Co-chair, Biomarker Assay Validation Committee. Legacy Wyeth.
2010/4 – present. Senior Scientific Technical Leader, PDM Biomarker Research, Pfizer Inc.
Appearing: Day Two, Thursday 21 October 2010 2.15pm Values and Challenges in Applications of Biomarkers for Clinical Development
- Types of biomarkers that are commonly used in early clinical development.
- Values of biomarker results for decision making during early development
- Challenges and key considerations for the selection of biomarkers in support of clinical development
- Challenges and significance of reliable biomarker assays in early clinical studies
Zhaosheng Lin, Head of Biomarkers,
Pfizer Inc |
|
|
|
|
|
Reserve an exhibition stand at the Exploratory Clinical Development World Americas exhibition - book early to ensure optimum stand placement!
| |
Reserve a stand
For details contact
Claire Conway on +44 (0) 207 608 7058 |
|
|
|
|
|
|
|
|
|
